Insider Transactions in Q4 2025 at Artivion, Inc. (AORT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.51%
|
$225,000
$45.11 P/Share
|
|
Dec 08
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,572
-3.4%
|
$201,168
$44.42 P/Share
|
|
Dec 03
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
30,921
-3.72%
|
$1,391,445
$45.46 P/Share
|
|
Dec 03
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,921
+3.58%
|
$896,709
$29.62 P/Share
|
|
Dec 03
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
7,315
-2.26%
|
$329,175
$45.3 P/Share
|
|
Dec 02
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
30,921
-3.72%
|
$1,391,445
$45.56 P/Share
|
|
Dec 02
2025
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,921
+3.58%
|
$896,709
$29.62 P/Share
|
|
Dec 01
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
750
-0.55%
|
-
|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
47,376
-18.89%
|
$2,131,920
$45.13 P/Share
|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
47,376
+25.58%
|
$663,264
$14.74 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
15,276
-9.42%
|
$672,144
$44.24 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+3.51%
|
$47,432
$14.74 P/Share
|
|
Nov 18
2025
|
Elizabeth A Hoff Director |
SELL
Open market or private sale
|
Direct |
4,200
-13.38%
|
$189,000
$45.1 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,394
-3.77%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.63%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,394
-3.12%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.02%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.24%
|
$270,000
$45.73 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,393
-3.77%
|
$287,685
$45.0 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,393
+3.63%
|
$185,397
$29.62 P/Share
|
|
Nov 14
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,393
-3.12%
|
$281,292
$44.67 P/Share
|
|
Nov 14
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,393
+3.02%
|
$185,397
$29.62 P/Share
|
|
Nov 13
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,482
-2.4%
|
$156,690
$45.86 P/Share
|
|
Nov 13
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,563
-3.2%
|
$295,335
$45.86 P/Share
|
|
Nov 13
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
4,993
-8.1%
|
$224,685
$45.86 P/Share
|
|
Nov 13
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,761
-3.41%
|
$259,245
$45.86 P/Share
|
|
Nov 13
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
34,210
-4.1%
|
$1,539,450
$45.86 P/Share
|
|
Nov 11
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-5.58%
|
$460,000
$46.18 P/Share
|
|
Nov 11
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.29%
|
$110,000
$11.03 P/Share
|
|
Nov 10
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,960
-1.72%
|
$130,240
$44.62 P/Share
|
|
Nov 10
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
2,566
-4.0%
|
$112,904
$44.62 P/Share
|
|
Nov 10
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,789
-1.22%
|
$78,716
$44.62 P/Share
|
|
Nov 10
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,373
-1.62%
|
$148,412
$44.62 P/Share
|
|
Nov 10
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
17,580
-2.06%
|
$773,520
$44.62 P/Share
|